EyePoint Pharmaceuticals Inc (EYPT)
8.95
+0.60
(+7.19%)
USD |
NASDAQ |
Nov 22, 16:00
8.935
-0.02
(-0.17%)
After-Hours: 20:00
EyePoint Pharmaceuticals Revenue (TTM): 45.71M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 45.71M |
| June 30, 2024 | 50.39M |
| March 31, 2024 | 50.02M |
| December 31, 2023 | 46.02M |
| September 30, 2023 | 42.52M |
| June 30, 2023 | 37.33M |
| March 31, 2023 | 39.79M |
| December 31, 2022 | 41.40M |
| September 30, 2022 | 42.42M |
| June 30, 2022 | 41.46M |
| March 31, 2022 | 38.91M |
| December 31, 2021 | 36.94M |
| September 30, 2021 | 32.53M |
| June 30, 2021 | 39.16M |
| March 31, 2021 | 34.27M |
| December 31, 2020 | 34.44M |
| September 30, 2020 | 35.94M |
| June 30, 2020 | 22.75M |
| March 31, 2020 | 25.84M |
| December 31, 2019 | 20.36M |
| September 30, 2019 | 12.22M |
| June 30, 2019 | 10.42M |
| March 31, 2019 | 4.141M |
| September 30, 2018 | 3.062M |
| June 30, 2018 | 2.961M |
| Date | Value |
|---|---|
| March 31, 2018 | 2.947M |
| December 31, 2017 | 2.609M |
| September 30, 2017 | 7.647M |
| June 30, 2017 | 7.539M |
| March 31, 2017 | 7.142M |
| December 31, 2016 | 6.876M |
| September 30, 2016 | 1.431M |
| June 30, 2016 | 1.62M |
| March 31, 2016 | 1.725M |
| December 31, 2015 | 1.729M |
| September 30, 2015 | 1.724M |
| June 30, 2015 | 26.56M |
| March 31, 2015 | 26.45M |
| December 31, 2014 | 28.11M |
| September 30, 2014 | 28.18M |
| June 30, 2014 | 3.473M |
| March 31, 2014 | 3.673M |
| December 31, 2013 | 2.194M |
| September 30, 2013 | 2.187M |
| June 30, 2013 | 2.143M |
| March 31, 2013 | 2.35M |
| December 31, 2012 | 2.375M |
| September 30, 2012 | 2.42M |
| June 30, 2012 | 3.526M |
| March 31, 2012 | 6.542M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
20.36M
Minimum
Dec 2019
50.39M
Maximum
Jun 2024
37.91M
Average
39.04M
Median
Revenue (TTM) Benchmarks
| Cassava Sciences Inc | -- |
| Regeneron Pharmaceuticals Inc | 13.85B |
| Adverum Biotechnologies Inc | -- |
| Regenxbio Inc | 84.33M |
| Editas Medicine Inc | 61.76M |